Palumbo Wealth Management LLC Has $236,000 Stake in Exagen Inc. (NASDAQ:XGN)

Palumbo Wealth Management LLC boosted its position in shares of Exagen Inc. (NASDAQ:XGN) by 14.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 76,364 shares of the company’s stock after buying an additional 9,695 shares during the period. Palumbo Wealth Management LLC owned approximately 0.44% of Exagen worth $236,000 at the end of the most recent quarter.

Separately, Renaissance Technologies LLC lifted its holdings in shares of Exagen by 93.3% in the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after acquiring an additional 45,476 shares during the last quarter. 75.25% of the stock is owned by institutional investors.

Exagen Price Performance

Shares of XGN stock traded up $0.08 on Thursday, reaching $2.59. The company had a trading volume of 970 shares, compared to its average volume of 42,443. The stock has a market capitalization of $45.03 million, a PE ratio of -2.59 and a beta of 1.32. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13. Exagen Inc. has a one year low of $1.30 and a one year high of $3.71. The business’s 50-day moving average is $2.90 and its 200 day moving average is $2.28.

Exagen (NASDAQ:XGN) last posted its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.20. The firm had revenue of $15.06 million during the quarter, compared to analysts’ expectations of $13.20 million. Exagen had a negative net margin of 30.56% and a negative return on equity of 78.90%. During the same quarter in the prior year, the business earned ($0.28) earnings per share. Equities research analysts forecast that Exagen Inc. will post -1.02 EPS for the current fiscal year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).